The Pulmonary Hypertension Association (PHA) will host a free workshop and fundraiser April 6-7 in Houston to raise awareness for pulmonary hypertension (PH) and support the greater PH community. The highlight of the weekend’s activities, which are aimed at educating, empowering, and supporting patients and caregivers, will be…
Tenax Therapeutics has secured global rights to oral and subcutaneous (under the skin) formulations of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Under a licensing agreement established with Orion Corp. in 2013, Tenax acquired developmental and commercial rights of…
People with pulmonary hypertension (PH) and high blood acetylcholine (ACh) levels show more severe symptoms and a poorer prognosis than those with lower ACh levels, a single-center study in China suggests. ACh is a neurotransmitter, a chemical messenger that allows nerve cells to communicate…
The hormone vasopressin may help improve oxygen levels and blood flow in newborns with acute pulmonary hypertension who fail to respond to treatment with inhaled nitric oxide, a study suggests. About two-thirds of newborns treated with vasopressin in the study, however, developed hyponatremia (a low level of sodium in…
The first healthy volunteer has been dosed in a Phase 1 trial testing ZMA001, Zymedi’s first-in-class investigational therapy for pulmonary arterial hypertension (PAH). The trial (NCT05967299), still recruiting participants at a clinical center in Bethesda, Maryland, will evaluate the safety, tolerability, and pharmacological properties of ZMA001.
Access to pulmonary rehabilitation programs for people with pulmonary hypertension (PH) and other chronic respiratory conditions is considerably more difficult for those living in rural U.S. regions than in urban areas, scientists report. Travel longer than 60 minutes affects more than 14 million U.S. residents of rural or underpopulated…
A Phase 3 trial of an oral formulation of levosimendan, dubbed TNX-103, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has enrolled the first participant. LEVEL (NCT05983250) is recruiting up to 152 adults with PH-HFpEF, ages 18-85,…
An investigational fixed-dose combination of macitentan and tadalafil in a single tablet (M/T STCT) led to improvements in blood flow and reductions in a biomarker of heart failure for people with pulmonary arterial hypertension (PAH) who were treatment naïve or previously received monotherapies, according to final…
Echocardiogram (ECG) measures that indicate the heart’s right ventricle (RV) and the pulmonary arteries are working poorly together to send blood to the lungs may help predict the presence of pulmonary hypertension (PH) in people with a certain type of heart failure, a recent publication indicates.
The U.S. Food and Drug Administration (FDA) has approved Cereno Scientific’s investigational drug CS1 in an extension of the ongoing Phase 2 clinical trial testing it in people with pulmonary arterial hypertension (PAH). This expanded access is sometimes called compassionate use. The…
A variant in the gene encoding the ALDH2 enzyme — fully known as aldehyde dehydrogenase 2 — was linked to an increased risk of pulmonary hypertension due to left heart disease (PH-LHD) among heart failure patients, a study in China found. Also called a polymorphism, meaning it involves one…
Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S. Food and Drug Administration (FDA) has delayed its decision to extend the use of Yutrepia — Liquidia‘s inhaled dry powder formulation of treprostinil — to people with…
Get regular updates to your inbox.